University of Maryland BS 05/1968 Zoology
State University of New York at Albany PHD 05/1973 Cell Biology
Woods Hole Marine Biology Laboratory Postdoctoral Fellow 1974 Biophysics

I began my academic career as an Assistant Professor at Harvard University and remained at Harvard until 1982, developing and using novel fluorescence-based reagents and imaging technologies to investigate fundamental cellular processes such as cell movements and cell division. I then moved to Carnegie Mellon University as a Professor of Biological Sciences and as Director of the Center for Fluorescence Research in the Biomedical Sciences. In 1991, I became the Director of the National Science Foundation-funded Center for Light Microscope Imaging and Biotechnology, and in 1995, I was named Vice Dean of CMU’s Division of Molecular Sciences. I continued to develop reagent and imaging technologies, while applying the technologies to understand fundamental processes in cells and tissues. Alan Waggoner and I co-founded Biological Detection Systems (BDS) to commercialize the multi-color cyanine dyes and research imaging platforms and it was acquired by Amersham-now GE Life Sciences. I left CMU in 1997 to found Cellomics, Inc., the company that developed High Content Screening (HCS). HCS was the foundation for a shift from focusing primarily on generating images to generating large-scale, quantitative image-based data from cells, tissues and small organisms. I was CEO of this company from 1997 through 2003 when it became part of ThermoFisher. I then founded a third company, Cellumen, that developed a predictive safety assessment platform using primary hepatocytes, multiplexed panels of reagents, reference safety databases and computational biology. I was CEO of Cellumen from 2004 until 2010 when it became part of Cyprotex, a British CRO. I also co-founded Cernostics, Inc., a fluorescence-based, tissue systems pathology company that has created a test for selecting at risk Barrett’s esophagus patients. I hold >25 U.S. patents, including six focused on cell-based imaging. I returned to academia at the end of 2010 to continue my academic interests that now link large-scale cell, tissue and human, biomimetic, tissue-engineered model profiling with computational and systems biology to optimize drug discovery and diagnostics based on quantitative systems pharmacology. I am also developing computational tools to identify and quantify heterogeneity.

1. Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle. Vernetti L, Gough A, Baetz N, Blutt S, Broughman JR, Brown JA, Foulke-Abel J, Hasan N, In J, Kelly E, Kovbasnjuk O, Repper J, Senutovitch N, Stabb J, Yeung C, Zachos NC, Donowitz M, Estes M, Himmelfarb J, Truskey G, Wikswo JP, Taylor DL. 2017. Sci Rep. Feb 8;7:42296. PubMed PMID: 28176881
2. Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems.Lee-Montiel F, George S, Gough A and Taylor DL. (2017). Expt Biol Med (April) DOI: 10.1177/1535370217703978
3. A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. Stern, AM, Schurdak, ME, Bahar, I, Berg, JM, DL Taylor. (2016) J Biomol Screen.21: 521-534.
4. Proteomic screening and lasso regression reveal differential signaling in insulin and insulin-like growth factor I pathways.Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang Y, Taylor DL, Lee AV and Lezon TR. (2016).  Mol Cell Proteomics 15:3045-3057 PMID: 27364358
5. Biologically relevant heterogeneity: Metrics and practical insights.Gough A, Stern, AM, Maier J, Lezon T, Shun T-Y, Chennubhotla C, Schurdak ME, Haney SA and Taylor DL. (2016).  SLAS Discovery 22: 213.
6. Liver metastases: Microenvironments and ex-vivo models. Clark AM, Ma B, Taylor DL, Griffith L, Wells A. Exp Biol Med (Maywood). 2016 Jul 6. pii: 1535370216658144. [Epub ahead of print] PMID: 27390264
7. Proteomic screening and lasso regression reveal differential signaling in insulin and insulin-like growth factor I pathways. Erdem C, Nagle AM, Casa AJ, Litzenburger BC, Wang YF, Taylor DL, Lee AV, Lezon TR. Mol Cell Proteomics. 2016 Jun 30. pii: mcp.M115.057729.  PMID: 27364358
8. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL. J Biomol Screen. 2016 Jul;21(6):521-34. doi: 10.1177/1087057116635818. Epub 2016 Mar 8. PMID: 26962875
9. High content analysis and cellular and tissue systems biology: a bridge between cancer cell biology and tissue-based diagnostics. Gough AG, Lezon T, Faeder JR, Chennubhotla C, Murphy RF, Critchley-Thorne R, Taylor DL. (2014).. In/The Molecular Basis of Cancer, 4^th Ed. (Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB) Elsevier, NY.
10. Pointwise mutual information quantifies intra-tumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. Spagnolo DM, Gyanchandai R, Al-Kofahi Y, Stern AM, Gough A, Meyer DE, Ginty F, Sarachan B, Fine J, Lee AV, Taylor DL, Chennubhotla SC. (2016). J. Pathol. Inform. 7: 47.
11. Fluorescent Protein Biosensors Applied to Microphysiological Systems. Senutovitch N*, Vernetti, L*, Boltz, R, DeBiasio, R, Gough, A, Taylor, DL. (2015) Exp Biol Med 240: 795-808. PMID: 25990438
12. A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. Gough A, Shun TY, Taylor DL, Schurdak M. Methods. 2016 Mar 1;96:12-26. doi: 10.1016/j.ymeth.2015.10.007. Epub 2015 Nov 4. PMID: 26476369
13. TissueCypher(™): A systems biology approach to anatomic pathology. Prichard JW, Davison JM, Campbell BB, Repa KA, Reese LM, Nguyen XM, Li J, Foxwell T, Taylor DL, Critchley-Thorne RJ. J Pathol Inform. 2015 Aug 31;6:48. doi: 10.4103/2153-3539.163987. eCollection 2015. PMID: 26430536